Palliative Thoracic ImmunoRT

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Oct 9, 2018

Keywords

ClinConnect Summary

This clinical trial, called Palliative Thoracic ImmunoRT, is studying a specific treatment approach for patients with stage IV non-small cell lung cancer. The goal is to see how well palliative thoracic radiotherapy works when given alongside PD-1 inhibitors, which are medications that help the immune system fight cancer. Participants will receive a standard dose of radiation over ten sessions, aiming to relieve symptoms and improve their quality of life.

To be eligible for this trial, patients must be at least 18 years old and have a confirmed diagnosis of stage IV lung cancer that cannot be cured with surgery or other treatments. They should also be planning to receive or currently receiving either nivolumab or pembrolizumab, which are types of PD-1 inhibitors. Participants need to have a life expectancy of more than three months and be able to complete questionnaires about their health. It's important to note that there are some conditions that would exclude a person from joining, such as previous treatments that could interfere with the study or certain medical histories. If you or someone you know might qualify, this trial could offer an additional option for managing lung cancer symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathologically confirmed AJCC 7th/8th edition Stage IV adenocarcinoma or squamous cell carcinoma not eligible for curative treatment.
• • 2. Indication and suitability to receive palliative radiotherapy to the thorax (30Gy/10).
• • 3. Receiving or planned to receive nivolumab or pembrolizumab
• • 4. Prior history of systemic chemotherapy is permitted given a washout period of 4 weeks
• • 5. Age 18 or older
• • 6. ECOG Performance Status 0-2
• • 7. Life expectancy greater than 3 months
• • 8. Able and willing to provide informed consent
• • 9. Able to complete patient reported outcome questionnaires
• Exclusion Criteria:
• • 1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia
• • 2. Previous history of thoracic radiotherapy with an overlapping field
• • 3. Previous history of checkpoint inhibitor related pneumonitis or esophagitis
• • 4. Pregnancy